不同剂量国产rhG-CSF预防肿瘤化疗所致白细胞减少的临床观察

Clinical Observation of Domestic made rhG CSF at Different Dosages in Prevention of Neutropenia Caused by Chemotherapy

１４１例经病理检查确诊的恶性肿瘤，包括肺癌、乳腺癌、淋巴瘤、卵巢癌分别应用同样方案和剂量的联合化疗。其中两组共４７例患者采用交叉自身配对对照的方法进行两疗程化疗，一疗程于化疗结束２４ｈ后加用国产ｒｈＧ－ＣＳＦ３００μｇ／日皮下注射，为高剂量组（Ｔ１），另一疗程化疗后不加用者作对照组（Ｃ）；另两组各４７例均进行一疗程化疗；化疗结束后的ｒｈＧ－ＣＳＦ剂量分别为１５０μｇ／日和７５μｇ／日，作为中剂量组（Ｔ２）和低剂量组（Ｔ３），ｒｈＧ－ＣＳＦ用法为连用１０天或当ＡＮＣ降至最低值后回升超过５×１０９／Ｌ两次以上停药。比较四组患者化疗后中性粒细胞绝对数（ＡＮＣ）的动态变化，以及化疗后ＡＮＣ降低的程度和ＡＮＣ减少持续时间、最低值的差异。结果证明，各剂量组ｒｈＧ－ＣＳＦ均可减轻化疗后ＡＮＣ降低的程度，缩短粒细胞缺乏症的持续时间，促进ＡＮＣ的恢复，无明显毒副反应，可作为肿瘤化疗中有价值的辅助药物。

One hundred and forty one cases of malignancies including lung cancer, breast cancer, non Hodgkin′s lymphoma, ovarian cancer were treated by combination chemotherapy of same regimens and doses. Among them, 47 cases were divided into two groups. After one cycle of chemotherapy, one group received rhG CSF 300ug (T1 group) and another group received none after chemotherapy (C group).The other two groups of 47 cases received rhG CSF 150μg (T2 group) and 75μg (T3 group) after one cycle of chemotherapy respectively. The changes of absolute neutrophil count (ANC) were observed after chemotherapy for these 4 groups.The results showed that neutropenia after chemotherapy could be prevented or attenuated in the treated groups (T1, T2, T3 groups) and that the neutropenia if occured recovered earlier as compared with the control group. It was found that the larger the dose of rhG CSF was given the better the effect of neutrophilic recovery was achieved. No evident side effect occurred. The study confirmed the value of domestic made rhG CSF as an adjuvant in preventing post chemotherapy neutropenia.